J Immunother Cancer August 2021 PMID 34413166

Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis.

Danny Rischin, Nikhil I Khushalani, Chrysalyne D Schmults, Alexander Guminski, Anne Lynn S Chang, Karl D Lewis, Annette M Lim, Leonel Hernandez-Aya, Brett G M Hughes, Dirk Schadendorf, Axel Hauschild, Alesha A Thai, Elizabeth Stankevich, Jocelyn Booth, Suk-Young Yoo

Full text PDF Download social card

Mentions

Peak: 2 in Aug 2021

across 3 sources since Aug 2021

Extended reach

22,165

potential audience

Total likes

Video views

372

Mentions per month

Aug 2021 – Sep 2024

Where it's discussed

X / Twitter4 posts
News2 articles
YouTube1 videos

AI synopsis

What people are saying

The overall sentiment shows strong support and high interest, evidenced by comments on the impressive 88% durability of responses and the implications for watch-and-wait strategies, with tone and word choices such as 'impressive' and 'raises the option' reflecting enthusiasm and significance for future treatment approaches.

AgreementModerate agreement

Most discussions recognize and support the positive findings of the study, highlighting the long-term response rates and quality of life improvements.

InterestHigh interest

The posts reflect high interest due to the focus on durable responses, long-term outcomes, and potential changes in treatment approaches.

EngagementModerate engagement

Some posts engage deeply by referencing specific metrics like the 88% response durability and suggesting clinical implications, but many are more surface-level mentions.

ImpactHigh impact

The shared discussions emphasize the study's importance for advancing treatment options and its potential to influence clinical practice, indicating high perceived impact.

Abstract in brief

This study pooled data from three groups of patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab, showing an overall objective response rate of 46.1% and durable responses with many patients still responding after a year.
The treatment led to early and sustained improvements in quality of life and pain, with responders experiencing significantly better outcomes, and the median overall survival was not reached, indicating promising long-term benefits.
As the largest dataset for this type of treatment, the results confirm that cemiplimab has strong and lasting effectiveness in treating advanced CSCC, including increased complete response rates over time.]

Read the full abstract

All mentions

Cemiplimab Efficacy in Advanced Cutaneous Squamous Cell Carcinoma Insights

This study pooled data from three groups of patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab, showing an overall objective response rate of 46.1% and durable responses with many patients…

BMJ Group · Aug 24, 2021 372 views

Michael Gensheimer

@MFGensheimer · X

Sep 9, 2024 · 477 followers View post →

@gulleyj1

@gulleyj1 · X

Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma https://t.co/e5QovkA82V

Sep 10, 2021 · 1 like · 7,509 followers View post →

Journal for ImmunoTherapy of Cancer

@jitcancer · X

Sep 2, 2021 · 9,313 followers View post →

Shima Ghavimi

@ShimaghavimiMD · X

RT @jitcancer: JITC's first video abstract has published in "Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squ…

Aug 19, 2021 · 1 share · 4,492 followers View post →